40. Events after balance sheet date
On 12 March 2015, Janssen Pharmaceutica and Galapagos NV terminated their research alliance and option agreements to develop and commercialize compounds for the treatment of inflammation initially focusing on RA. All rights to the candidate drugs developed under these agreements are returned to Galapagos.
The consolidated financial statements of Galapagos were approved by the Board of Directors and authorized for issue, on 26 March 2015. They were signed on its behalf by:
Onno van de Stolpe
Managing Director and CEO
26 March 2015